OncoMatch/Clinical Trials/NCT06976190
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Is NCT06976190 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including MRG003 + Pucotenlimab and Gemcitabine, Docetaxel, or Capecitabine for recurrent or metastatic nasopharyngeal carcinoma.
Treatment: MRG003 + Pucotenlimab · Gemcitabine, Docetaxel, or Capecitabine — This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: mmae/mmaf adc drugs
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
No severe cardiac dysfunction, left ventricular ejection fraction (LVEF) ≥50%
No severe cardiac dysfunction, left ventricular ejection fraction (LVEF) ≥50%. Organ functions and coagulation function must meet the basic requirements.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify